Entrada Therapeutics Files Definitive Proxy Statement
Ticker: TRDA · Form: DEF 14A · Filed: Apr 25, 2025 · CIK: 1689375
| Field | Detail |
|---|---|
| Company | Entrada Therapeutics, Inc. (TRDA) |
| Form Type | DEF 14A |
| Filed Date | Apr 25, 2025 |
| Risk Level | low |
| Sentiment | neutral |
Sentiment: neutral
Topics: proxy-statement, annual-meeting, governance
Related Tickers: TRDA
TL;DR
Entrada Therapeutics (TRDA) proxy filing out for annual meeting votes - directors & auditors up for approval.
AI Summary
Entrada Therapeutics, Inc. filed its definitive proxy statement on April 25, 2025, for its annual meeting of stockholders. The filing outlines the proposals to be voted on, including the election of directors and the ratification of the appointment of its independent registered public accounting firm. The company is seeking shareholder approval for these routine corporate governance matters.
Why It Matters
This filing is crucial for shareholders as it details the agenda for the upcoming annual meeting, allowing them to make informed voting decisions on company leadership and financial oversight.
Risk Assessment
Risk Level: low — This is a routine proxy statement for an annual meeting, not indicating any unusual financial or operational risks.
Key Players & Entities
- Entrada Therapeutics, Inc. (company) — Registrant
- 0001104659-25-039000 (filing_id) — Accession Number
- 20250425 (date) — Filing Date
- 20250611 (date) — Conformed Period of Report
FAQ
What is the purpose of this DEF 14A filing?
This filing is a definitive proxy statement filed by Entrada Therapeutics, Inc. for its annual meeting of stockholders, outlining proposals for shareholder votes.
When was this filing submitted to the SEC?
The filing was submitted on April 25, 2025.
What is the company's fiscal year end?
The company's fiscal year ends on December 31.
What is the company's primary business sector?
The company operates in Pharmaceutical Preparations (SIC code 2834).
What is the company's SEC file number?
The SEC file number for Entrada Therapeutics, Inc. is 001-40969.
Filing Details
This Form DEF 14A (Form DEF 14A) was filed with the SEC on April 25, 2025 regarding Entrada Therapeutics, Inc. (TRDA).